PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Vermorken, Jan Baptist
TI  - Results of the EXTREME Study
DP  - 2007 Sep 01
TA  - MD Conference Express
PG  - 15--15
VI  - 7
IP  - 3
4099  - http://mdc.sagepub.com/content/7/3/15.short
4100  - http://mdc.sagepub.com/content/7/3/15.full
AB  - Overall survival for patients with head and neck cancers is significantly prolonged with the addition of cetuximab to platinum-based chemotherapy, according to results of the phase 3 EXTREME study. In addition, adding cetuximab did not increase toxicities above those characteristic of platinum-based therapy.